Polycystic Kidney Disease - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 73 pages report, published by Global Markets Direct

Keywords : Polycystic Kidney Disease Therapeutic Products under Development, Key Players in Polycystic Kidney Disease Therapeutics, Polycystic Kidney Disease Pipeline Overview, Polycystic Kidney Disease Pipeline, Polycystic Kidney Disease Pipeline Assessment

Report ThumbnailSeptember-2013
Polycystic Kidney Disease - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Polycystic Kidney Disease - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Polycystic Kidney Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease. Polycystic Kidney Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Polycystic Kidney Disease.
- A review of the Polycystic Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Polycystic Kidney Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Polycystic Kidney Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Polycystic Kidney Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Polycystic Kidney Disease, H2 2013 9
  • Products under Development for Polycystic Kidney Disease - Comparative Analysis, H2 2013 10
  • Products under Development by Companies, H2 2013 11
  • Products under Investigation by Universities/Institutes, H2 2013 13
  • Late Stage Products, H2 2013 14
  • Mid Clinical Stage Products, H2 2013 15
  • Early Clinical Stage Products, H2 2013 16
  • Discovery and Pre-Clinical Stage Products, H2 2013 17
  • Assessment by Monotherapy Products, H2 2013 30
  • Assessment by Combination Products, H2 2013 31
  • Assessment by Route of Administration, H2 2013 32
  • Assessment by Stage and Route of Administration, H2 2013 33
  • Assessment by Molecule Type, H2 2013 34
  • Assessment by Stage and Molecule Type, H2 2013 35
  • List of Tables
  • Number of Products Under Development for Polycystic Kidney Disease, H2 2013 9
  • Products under Development for Polycystic Kidney Disease - Comparative Analysis, H2 2013 10
  • Number of Products under Development by Companies, H2 2013 12
  • Number of Products under Investigation by Universities/Institutes, H2 2013 13
  • Comparative Analysis by Late Stage Development, H2 2013 14
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 15
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 16
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 17
  • Products under Development by Companies, H2 2013 18
  • Products under Investigation by Universities/Institutes, H2 2013 19
  • Emergent BioSolutions Inc., H2 2013 20
  • Plexxikon Inc., H2 2013 21
  • Pfizer Inc., H2 2013 22
  • Synta Pharmaceuticals Corp., H2 2013 23
  • Metabolic Solutions Development Co., H2 2013 24
  • IC-MedTech, Inc., H2 2013 25
  • Endocyte, Inc., H2 2013 26
  • ManRos Therapeutics, H2 2013 27
  • Napo Pharmaceuticals, Inc., H2 2013 28
  • DiscoveryBiomed, Inc., H2 2013 29
  • Assessment by Monotherapy Products, H2 2013 30
  • Assessment by Combination Products, H2 2013 31
  • Assessment by Stage and Route of Administration, H2 2013 33
  • Assessment by Stage and Molecule Type, H2 2013 35
  • Polycystic Kidney Disease Therapeutics - Drug Profile Updates 56
  • Polycystic Kidney Disease Therapeutics - Discontinued Products 64
  • Polycystic Kidney Disease Therapeutics - Dormant Products 65
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Polycystic Kidney Disease Overview 8
  • Therapeutics Development 9
  • An Overview of Pipeline Products for Polycystic Kidney Disease 9
  • Polycystic Kidney Disease Therapeutics under Development by Companies 11
  • Polycystic Kidney Disease Therapeutics under Investigation by Universities/Institutes 13
  • Late Stage Products 14
  • Comparative Analysis 14
  • Mid Clinical Stage Products 15
  • Comparative Analysis 15
  • Early Clinical Stage Products 16
  • Comparative Analysis 16
  • Discovery and Pre-Clinical Stage Products 17
  • Comparative Analysis 17
  • Polycystic Kidney Disease Therapeutics - Products under Development by Companies 18
  • Polycystic Kidney Disease Therapeutics - Products under Investigation by Universities/Institutes 19
  • Companies Involved in Polycystic Kidney Disease Therapeutics Development 20
  • Emergent BioSolutions Inc. 20
  • Plexxikon Inc. 21
  • Pfizer Inc. 22
  • Synta Pharmaceuticals Corp. 23
  • Metabolic Solutions Development Co. 24
  • IC-MedTech, Inc. 25
  • Endocyte, Inc. 26
  • ManRos Therapeutics 27
  • Napo Pharmaceuticals, Inc. 28
  • DiscoveryBiomed, Inc. 29
  • Polycystic Kidney Disease - Therapeutics Assessment 30
  • Assessment by Monotherapy Products 30
  • Assessment by Combination Products 31
  • Assessment by Route of Administration 32
  • Assessment by Molecule Type 34
  • Drug Profiles 36
  • bosutinib - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • MSDC-0160 - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • tolvaptan - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • tolvaptan - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • tolvaptan - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • octreotide-LAR - Drug Profile 46
  • Product Description 46
  • Mechanism of Action 46
  • R&D Progress 46
  • TNFR x TWEAKR - Drug Profile 47
  • Product Description 47
  • Mechanism of Action 47
  • R&D Progress 47
  • lanreotide acetate - Drug Profile 48
  • Product Description 48
  • Mechanism of Action 48
  • R&D Progress 48
  • sirolimus - Drug Profile 49
  • Product Description 49
  • Mechanism of Action 49
  • R&D Progress 49
  • Polycystic Kidney Disease Program - Drug Profile 50
  • Product Description 50
  • Mechanism of Action 50
  • R&D Progress 50
  • Program For Polycystic Kidney Disease - Drug Profile 51
  • Product Description 51
  • Mechanism of Action 51
  • R&D Progress 51
  • Drug For Polycstic Kidney Disease - Drug Profile 52
  • Product Description 52
  • Mechanism of Action 52
  • R&D Progress 52
  • Drugs For Human Ciliopathies - Drug Profile 53
  • Product Description 53
  • Mechanism of Action 53
  • R&D Progress 53
  • GLG-302 - Drug Profile 54
  • Product Description 54
  • Mechanism of Action 54
  • R&D Progress 54
  • STA-2842 - Drug Profile 55
  • Product Description 55
  • Mechanism of Action 55
  • R&D Progress 55
  • Polycystic Kidney Disease Therapeutics - Drug Profile Updates 56
  • Polycystic Kidney Disease Therapeutics - Discontinued Products 64
  • Polycystic Kidney Disease Therapeutics - Dormant Products 65
  • Polycystic Kidney Disease - Product Development Milestones 66
  • Featured News & Press Releases 66
  • Aug 29, 2013: Otsuka Receives Complete Response Letter from U.S. Food and Drug Administration for Tolvaptan for Use in Patients with Autosomal Dominant Polycystic Kidney Disease 66
  • Aug 05, 2013: U.S. Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee Recommends Not to Approve Otsuka Pharmaceutical’s Tolvaptan for Use in Autosomal Dominant Polycystic Kidney Disease 66
  • Jun 03, 2013: Otsuka Pharma Submits New Drug Application In Japan For Tolvaptan For Treatment Of Autosomal Dominant Polycystic Kidney Disease 67
  • Apr 12, 2013: Otsuka Pharma Announces FDA Acceptance Of NDA For Tolvaptan 67
  • Mar 01, 2013: Otsuka Canada Pharma Updates Safety Information For Polycystic Kidney Disease Drug Samsca 67
  • Jan 25, 2013: Otsuka And FDA Notify Healthcare Professionals Of Significant Liver Injury Associated With Use Of Samsca 68
  • Nov 04, 2012: Otsuka’s Investigational Compound For Autosomal Dominant Polycystic Kidney Disease, Tolvaptan, Meets Primary Endpoint In Phase III Clinical Trial 68
  • Oct 07, 2010: The Johns Hopkins Polycystic Kidney Disease Center includes DiscoveryBioMed, Inc. in its program. 70
  • Oct 26, 2009: Napo Acquires Rights To Additional CFTR Technology 70
  • May 05, 2009: Napo Pharmaceuticals Initiates Preclinical Development Of A Novel CFTR Inhibitor Using Preclinical Resources Offered By The National Institute Of Allergy And Infectious Diseases (NIAID) 71
  • Appendix 72
  • Methodology 72
  • Coverage 72
  • Secondary Research 72
  • Primary Research 72
  • Expert Panel Validation 72
  • Contact Us 73
  • Disclaimer 73

Please select a license type

Share

Related Products

Global Markets DirectPolycystic Kidney Disease - Pipeline Review, H2 2013Product ThumbnailPolycystic Kidney Disease - Pipeline Review, H2 2013, Industry ReportProduct #: 113294
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved